Related Experiment Video
Updated: May 22, 2025
07:31
Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings
Published on: May 7, 2020
7.1K
Clinical pharmacy activities specific to patients treated with lithium
Candice Niot1, Elodie Cuvelier2, Arnaud Leroy3
1Service pharmacie, CHU de Nice, 06001 Nice, France.
L'Encephale
|March 15, 2025
Summary
Poor medication compliance with lithium is common. Personalized pharmaceutical interviews improved patient understanding and adherence to lithium treatment, showing promise for better drug management in psychiatric care.
Area of Science:
- Psychiatric Pharmacy
- Pharmacovigilance
- Patient Adherence
Background:
- Lithium treatment is associated with suboptimal medication compliance, ranging from 43-46%.
- Poor adherence to lithium therapy can lead to treatment relapse and adverse toxicity.
- Enhanced patient understanding of treatment principles is crucial for improving medication adherence.
Purpose of the Study:
- To assess medication adherence and patient understanding of lithium and its potential adverse effects.
- To evaluate the feasibility and impact of personalized pharmaceutical interviews for lithium-treated patients.
- To determine the effectiveness of targeted pharmaceutical interventions in a clinical pharmacy setting.
Main Methods:
- Implementation of self-assessment questionnaires, including the Medication Adherence Rating Scale and Lithium Knowledge Test.
- Conducting personalized pharmaceutical interviews focused on lithium therapy and risk management.
- Recording interview duration, medical team satisfaction, and encountered challenges.
Main Results:
- Twenty patients participated in the 6-month study, each receiving a personalized interview.
- Patient adherence, knowledge, and risk awareness scores were measured, with specific targets set for each.
- The median time for interviews was 95 minutes per patient, with 70-100% medical team satisfaction.
Conclusions:
- Personalized pharmaceutical interviews can improve medication compliance and patient understanding of lithium therapy.
- The study highlights the potential of targeted pharmaceutical interventions to optimize drug management in psychiatric patients.
- High patient and medical team satisfaction suggests the sustainability of these pharmaceutical activities.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
106
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:28Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
01:26Psychosis: Goals of Pharmacotherapy
101
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
101
01:20Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
67
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
67